<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259376</url>
  </required_header>
  <id_info>
    <org_study_id>EFC4788</org_study_id>
    <secondary_id>SR33589B</secondary_id>
    <nct_id>NCT00259376</nct_id>
  </id_info>
  <brief_title>American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm</brief_title>
  <acronym>ADONIS</acronym>
  <official_title>American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
      rhythm after electrical, pharmacological or spontaneous conversion of atrial
      fibrillation/atrial flutter (AF/AFL).

      To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
      AF/AFL recurrence.

      To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, parallel arm, placebo-controlled, multicentre, multinational, phase
      III study.

      To be eligible, patients must be in normal sinus rhythm at randomisation and must have an
      ECG-documented history of recent AF/AFL reverted to normal sinus rhythm by electrical,
      pharmacological or spontaneous conversion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrence</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- AF/AFL related symptoms collected at the time of ECG/TTEM recording,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- mean ventricular rate during AF/AFL at first recorded AF/AFL recurrence (12-lead ECG or TTEM)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- time from presumed study drug near steady state defined as D5 midnight to first documented AF/AFL recurrence as indicated by ECG/TTEM recording.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">629</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Dronedarone 400mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dronedarone 400mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>matching placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone (SR33589)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Dronedarone 400mg bid</arm_group_label>
    <other_name>MultaqÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at
             the time of randomisation and with at least one ECG-documented AF/AFL episode in the
             last 3 months.

        Exclusion Criteria:

          -  MAIN CRITERIA (non-exhaustive list, see protocol for details):

        Women of childbearing potential without adequate birth control, Pregnant women,
        Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which
        increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Australia administrative office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 Sep 6;357(10):987-99.</citation>
    <PMID>17804843</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2005</study_first_submitted>
  <study_first_submitted_qc>November 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>February 12, 2010</last_update_submitted>
  <last_update_submitted_qc>February 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>International Clinical Development, Clinical Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Flutter</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Anti-Arrhythmia agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

